ROS1-positive non-small cell lung cancer
GPTKB entity
Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
non-small cell lung cancer subtype
|
| gptkbp:associatedWith |
younger patients
never-smokers |
| gptkbp:can_develop |
resistance mutations
|
| gptkbp:diagnosedBy |
gptkb:fluorescence_in_situ_hybridization
next-generation sequencing immunohistochemistry |
| gptkbp:has_biomarker |
ROS1 fusion protein
|
| gptkbp:has_genetic_alteration |
ROS1 gene rearrangement
|
| gptkbp:has_primary_site |
gptkb:cancer
|
| gptkbp:has_resistance_mechanism |
ROS1 G2032R mutation
activation of bypass signaling pathways |
| gptkbp:has_targeted_therapy |
tyrosine kinase inhibitors
|
| https://www.w3.org/2000/01/rdf-schema#label |
ROS1-positive non-small cell lung cancer
|
| gptkbp:most_common_histology |
gptkb:cancer
|
| gptkbp:prevalence |
1-2% of non-small cell lung cancer cases
|
| gptkbp:treatment |
gptkb:ceritinib
gptkb:crizotinib gptkb:lorlatinib gptkb:entrectinib gptkb:repotrectinib |
| gptkbp:type |
gptkb:cancer
ROS1-rearranged cancer |
| gptkbp:bfsParent |
gptkb:repotrectinib
gptkb:PF-02341066 |
| gptkbp:bfsLayer |
8
|